Crucell Strengthens its Vaccine Sales in the UK with a Dedicated Marketing and Sales Organization.

(From Hugin)

Leiden, The Netherlands (September 30, 2009) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced the launch of its own dedicated marketing and sales organization in the United Kingdom by acquiring an experienced team, to further strengthen its vaccine sales position in one of the largest vaccine markets in Europe.

Crucell's UK team will market and sell Crucell's travel vaccines Epaxal (aluminum-free hepatitis A vaccine), Vivotif (oral typhoid fever vaccine) and Dukoral (oral vaccine against cholera and travelers' diarrhea), as well as its registered virosomal adjuvanted influenza vaccine Inflexal V. …